Peter Cancelmo Net Worth

Peter Cancelmo biography

Peter B. Cancelmo J.D. serves as Vice President, General Counsel, Secretary of the Company. Mr. Cancelmo has served as our vice president, general counsel and secretary since June 2019. He joined Omeros as deputy general counsel, corporate governance and securities in January 2019. Prior to joining Omeros, Mr. Cancelmo was a principal and shareholder at Garvey Schubert Barer, P.C., where he represented clients in the life sciences and other technology industries in mergers, acquisitions, strategic alliances, public and private securities offerings, and a range of other corporate, commercial and financial transactions. He served as chair of the firm’s business practice group from 2016 until his departure in December 2018. Mr. Cancelmo previously practiced corporate and transactional law at Davies, Ward, Philips and Vineberg LLP, in New York, and Choate, Hall & Stewart LLP, in Boston. Mr. Cancelmo received his J.D. from Boston University and his B.A. from Saint Michael’s College.

What is the salary of Peter Cancelmo?

As the Vice President, General Counsel e Secretary of Omeros, the total compensation of Peter Cancelmo at Omeros is $705,959. There are 4 executives at Omeros getting paid more, with Gregory Demopulos having the highest compensation of $4,825,130.

How old is Peter Cancelmo?

Peter Cancelmo is 41, he's been the Vice President, General Counsel e Secretary of Omeros since 2019. There are 30 older and no younger executives at Omeros. The oldest executive at Omeros Corporation is Ray Aspiri, 83, who is the Independent Director.

What's Peter Cancelmo's mailing address?

Peter's mailing address filed with the SEC is 201 ELLIOTT AVENUE WEST, , SEATTLE, WA, 98119.

Insiders trading at Omeros

Over the last 15 years, insiders at Omeros have traded over $719,810 worth of Omeros stock and bought 141,095 units worth $829,835 . The most active insiders traders include Gregory A Md Demopulos, Marcia S. Kelbon e Daniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of $97,792. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth $25,200.

What does Omeros do?

omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Omeros executives and stock owners

Omeros executives and other stock owners filed with the SEC include:

• Gregory Demopulos,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Gregory A. Demopulos,
  Co-Founder, Chairman, CEO & Pres
• Dr. Gregory A. Demopulos M.D.,
  Co-Founder, Chairman, CEO & Pres
• Michael Jacobsen,
  Chief Accounting Officer, Vice President - Finance, Treasurer
• Peter Cancelmo,
  Vice President, General Counsel, Secretary
• Michael A. Jacobsen,
  Chief Accounting Officer, VP of Fin. & Treasurer
• Peter B. Cancelmo J.D.,
  VP, Gen. Counsel & Corp. Sec.
• Thomas Bumol,
  Independent Director
• Thomas Cable,
  Lead Independent Director
• Ray Aspiri,
  Independent Director
• Arnold Hanish,
  Independent Director
• Leroy Hood,
  Independent Director
• Rajiv Shah,
  Independent Director
• Peter Demopulos,
  Director
• Kurt Zumwalt,
  Independent Director
• Timothy Duffy,
  Vice President - Business Development
• J. Steven Whitaker,
  Vice President, Chief Medical Officer
• Tina Quinton,
  Vice President - Patents
• Catherine Melfi,
  Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer
• Bruce Meiklejohn,
  Vice President - Chemistry, Manufacturing and Controls
• Daniel Kirby,
  Vice President, Chief Commercial Officer
• Christopher Bral,
  Vice President - Nonclinical Development
• George Gaitanaris,
  Chief Scientific Officer, Vice President - Science
• Dr. J. Steven Whitaker J.D., M.D.,
  VP of Clinical Devel. & Chief Medical Officer
• Dr. Pamela Pierce Palmer M.D., Ph.D.,
  Co-Founder
• Nadia Dac,
  Chief Commercial Officer
• Dr. Catherine A. Melfi,
  Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
• Dr. J. Steven Whitaker,
  VP of Clinical Devel. & Chief Medical Officer
• Peter W. Williams,
  VP of HR
• Dr. George A. Gaitanaris M.D., Ph.D.,
  Chief Scientific Officer & VP of Science
• Dr. Pamela Pierce Palmer,
  Co-Founder
• Marcia S. Kelbon,
  VP Patent and General Counsel
• Diana T. Perkinson,
  Director
• Daniel K Spiegelman,
  Director
• Jean Philippe Tripet,
  Director